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ABSTRACT
Acute Myeloid Leukemia (AML) is associated with reduced levels or activity of the
transcription factor PU.l in mice and humans. However, little is known about how
reduced levels of this essential regulator of hematopoiesis causes AML. We hypothesize
that reduced levels of PU.l cause AML by promoting self-renewal of myeloid
progenitors through cell-cycle deregulation. Using mice homozygous for an allele of
PU.l (encoded by Sfpil) which expresses PU.l at -20% of normal levels (Sfpilm /m ), we
show that these mice are runted and display an abnormal skeletal phenotype. This is due
to an absence of TRAP+ osteoclasts and a failure to upregulate p57kip2 in chrondrocytes.
In addition to the skeletal phenotype, a large expansion of immature myeloid cells occurs
in the spleen of newborn SfpilBWm mice suggesting unregulated cell cycle in vivo.
SfpilBN/BN myeloid precursors had indefinite colony formation ability when grown in
differentiating media, which suggests self-renewal. Next, restoration of PU.l using a
retroviral vector opposed self-renewal and promoted differentiation in vitro seen by an
increase in CD lib and a decrease in c-Kit levels. We have identified E2fl as a target
gene of PU. 1, which regulates cell cycle progression. This model system will allow us to
further understand the mechanisms behind hematopoiesis and leukemia. Manipulation of
PU.l levels might be used as a treatment to promote myeloid differentiation and cell
cycle arrest.

Keywords: Acute Myeloid Leukemia, AML, Purine Rich Box 1, PU.l, hematopoiesis,
transcriptional regulation, cell cycle regulation, and immunology.
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CHAPTER 1: INTRODUCTION
1.1 Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a relatively rare but devastating form of
leukemia characterized by a maturation block in the myeloid lineage of hematopoiesis.
According to the National Cancer Institute, there were over 12,000 new diagnoses of
AML in the U.S.A., and over 8,000 deaths in 2010 alone (1). AML is diagnosed when
the marrow contains more than 30% blasts that are of myeloid lineage (2). From 20042008, the median age at diagnosis for AML was 67 years old (1). These numbers show
that AML is the most common acute leukemia affecting adults, however all age groups
can develop AML (3). The most common causes of death in AML patients stem from
bone marrow failure due to insufficient hematopoiesis (2, 4). The most recent five year
relative survival rate for AML is 24.2%, however there is variability depending on the
age and subtype of AML at diagnosis (1,2, 4). The subtype of AML is based on the
French-American-British (FAB) classification system. This system divides AML into
nine distinct subtypes of AML based on the myeloid lineage involved and the degree of
differentiation (4). Subtypes are based on morphological appearance, histological staining
results and translocations or genes involved (Table 1.1). Once an individual is diagnosed
with AML, the goal of the first phase of treatment is to produce complete remission of
the disease, which is defined as marrow which contains less than 5% blasts, a neutrophil
count higher than 1000, and a platelet count over 100,000 (4, 5). The goal of the second
phase of treatment is to extend the length of remission, since once a patient has been in
remission more than 3 years, the likelihood of relapse declines to less than 10% (6).
Since transcription factors play a central role in normal hematopoiesis, it
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Table 1.1 FAB Classification of AML and associated genetic abnormalities
Table 1.1 adapted from Lowenberg et al. 1999(4)

FAB
Subtype

C om m on Nam e
(% o f cases)

R esults o f Staining
M yeloperoxidase

Sudan
Black

N on
specific
esterases

MO

Acute myeloid leukemia with
minimal differentiation (3%)

Negative

Negative

Negative

Ml

Acute myeloblastic leukemia
without maturation
(15-20%)
Acute myeloblastic leukemia
with maturation (25-30%)

Positive

Positive

Negative

Positive

Positive

Negative

M3

Acute promyelocytic
leukemia (5-10%)

Positive

Positive

Negative

M4

Acute myelomonocytic
leukemia (20%)

Positive

Positive

Positive

M4Eo

Acute myelomonocytic
leukemia with abnormal
eosinophils (5-10%)
Acute monocytic leukemia
(2-9%)
Erythroleukemia (3-5%)

Positive

Positive

Positive

Negative

Negative

Positive

Positive

Positive

Negative

Negative

Negative

Positive

M2

M5
M6
M7

Acute megakaiyocytic
leukemia (3-12%)

A ssociated
translocations and
rearrangem ents
(% o f cases)

G enes
Involved

Inv (3q26) and t(3;3)
(1%)

EVIl, PU.l,
RUNX1
c/EBPa

t(8;21) (40%) ,t(6;9)
(1%)

AML1-ETO,
DEK-CAN,
c/EBPa
t(15;17) (98%), t( 11; 17) PML-RARa,
(1%), t(5;17) (1%)
PLZF-RARa,
NPMRARa,
PU .l
MLL, DEK1lq23 (20%),
inv(3q26)
CAN, EVIl,
and t(3;3) (3%),
PU.l, c/EBPa
t(6;9) (1%)
CBFfi-MYHl 1,
inv (16),
t(16;16) (80%)
PU.l, c/EBPa
1lq23 (20%), t(8;16)
(2%)

MLL-MOZCBP, PU.l
PU.l

T(l;22) (5%)

GATAI
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should come as no surprise that transcription factors are frequently mutated or
dysregulated in many forms of AML (Table 1). The majority of AML subtypes display
chromosomal rearrangements or mutations of transcription factors that are normally
involved in hematopoiesis. Many cases of AML are associated with chromosomal
rearrangements of transcription factors, such as the t (8; 21) translocation that results in
the oncogenic RUNX1-ETO fusion protein. This fusion protein is found in up to 15% of
AML cases and results in the RUNX1 DNA binding domain being fused to the ETO
repressor which results in repression of the transcription factors PU.l, c/EBPa and
RUNX1 (7, 8). Interestingly other fusion proteins such as the FLT3-ITD protein and the
PML-RARa protein also result in the downregulation of PU.l (9, 10). Point mutations in
transcription factors can result in cases of AML. Table 1 shows that many transcription
factors are mutated in cases of AML and can be regarded as prognostic markers. Since
AML is characterized by a developmental block in hematopoiesis, knowledge of normal
hematopoiesis and its transcriptional regulation is critical.

1.2 Hematopoiesis
Hematopoiesis

is

the

development

of

all

blood

cell

lineages

from

a

hematopoietic stem cell (HSC). It is possible to identify HSCs by flow cytometry based
on expression of the following cell surface markers: c-Kit+, Thy-1.110, Sca-1+, Lineage’,
Mac-l'° (11-13). A hematopoietic stem cell is defined by two main properties, namely
self-renewal and multipotency. Self-renewal is defined as the ability to undergo many
cellular divisions while remaining undifferentiated. This includes the ability of dividing
asymmetrically, which allows one daughter cell to maintain the HSC population while
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allowing the second daughter cell to differentiate. Multipotency is the ability to
differentiate into cell types of multiple different lineages. The HSC has the ability to
generate progenitors which may differentiate into all lineages of cells in the blood in a
hierarchical fashion (14). The terminally differentiated cell types that a HSC may
produce include erythrocytes (red blood cells), megakaryocytes, macrophages,
neutrophils, eosinophils, basophils, mast cells, natural killer (NK) cells and B- and Tlymphocytes. These can all be distinguished based on the expression of unique cell
surface markers, gene expression or morphology.
In mammals, hematopoietic cells develop from the mesodermic layer of the embryo
which becomes commited or specialized towards a hematopoietic fate (14, 15). While
there are certain differences between humans and mice, mouse models provide us with
valuable information on the development and function of the hematopoietic system (16,
17). Hematopoiesis occurs in two waves at the following locations: the yolk sac, the
aorta-gonad mesonephros (AGM) region, the fetal liver, and finally the bone marrow (18)
(Figure 1.1).

The first wave, also known as primitive or embryonic hematopoiesis,

occurs in the blood islands of the yolk sac and AGM region at approximately 7.5 days
post coitum (d.p.c.)(19, 20) The yolk sac is the location of the production of erythrocytes
containing fetal hemoglobin, which allows for tissue oxygenation during development
(18). The AGM region produces many hematopoietic precursors (21). At approximately
9.5 d.p.c., primitive hematopoiesis is replaced by the second wave of hematopoiesis
termed definitive hematopoiesis. This occurs in the fetal liver with maximal
hematopoietic activity occurring 14.5 d.p.c. (12) Following 15 d.p.c., the amount of
hematopoiesis begins to decrease in the fetal liver which is thought to be a
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Figure 1.1 Temporal and spatial locations of hematopoiesis.

Hematopoiesis first

begins at the yolk sac at approximately 7 days post coitum (d.p.c.), followed by the aorta,
gonad, mesonephros (AGM) region. Fetal circulation begins at approximately 9 d.p.c., at
at which point hematopoiesis also begins to take place in the fetal liver where it is
maintained until it relocates to the bone marrow at approximately 20 d.p.c where it will
occur for the rest of the animal’s life (22).
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consequence of mobilization of HSC to the bone marrow (BM), spleen and accessory
lymphoid organs where it will remain for the remainder of life (22).
The pathways by which hematopoiesis occurs are currently the subject of debate
(23). The “classical” model of hematopoiesis states that lineages undergo hierarchical
binary divisions to drive development. In this scheme, the HSC first differentiates into
the common myeloid progenitor (CMP) or common lymphoid progenitor (CLP). The
CMP then differentiates into either the megakaryocyte/erythroid progenitor (MEP),
which

gives

rise

to

in

either

megakaryocytes

or

erythryocytes,

or

the

granulocyte/monocyte progenitor (GMP), which generates macrophages or granulocytes.
The CLP differentiates into either NK-cells, B cells, or T cells (24) (Figure 1.2A).
There are several alternative models of hematopoiesis proposed by multiple
groups such as the stochastic model, the sequential restriction model, myeloid-based
models, as well as models based on studies of transcription factors (25). One such
revised model was originally proposed by Adolfsson et al (26) (Figure 1.2B). In this
model, the HSC first differentiates into a multipotent progenitor (MPP). The MPP then
differentiates into either a megakaryocyte-erythroid progenitor (MEP), which leads to
megakaryocytes or erythroid cells, or a lymphoid-primed multipotent progenitor (LMPP).
The LMPP then differentiates into either the granulocyte-macrophage progenitor (GMP),
which leads to granulocytes or macrophages, or to the common lymphoid progenitor
(CLP), which leads to NK cells, B cells, and T cells (27).
Hematopoiesis is a complex and finely tuned process that is tightly controlled both
temporally and spatially. It is controlled by the extracellular environment as well as
intracellularly by combinations of transcription factors (28). Without proper control, this
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Figure 1.2 Classical and Stochastic Models of Hematopoiesis
(A) Classical model of hematopoiesis. This figure shows the classical model of
hematopoiesis. (B) Stochastic model of hematopoiesis. This figure shows an alternative
model of hematopoiesis as adapted from Adolfsson et al (26). Hematopoietic stem cell,
HSC; Multipotent Progenitor, MPP; Lymphoid Primed Multipotent Progenitor, LMPP;
Common Lymphoid Progenitor, CLP; Common Myeloid Progenitor, CMP; Granulocyte
Macrophage Progenitor, GMP; Megakaryocyte Erythrocyte Progenitor, MEP. PU.l
expression gradient is shown in by colour. The top portion of the being darkest indicating
highest expression of PU. 1 in these cells, while the bottom portion of the panel is the
lightest indicating the lowest expression of PU. 1.

Lowest

PU.1

---------- Concentration ---------- ^
Highest

A
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process may result in different diseases such as AML.

1.3 Transcriptional Regulation of Myeloid Cell Development
While the exact mechanism by which the HSC differentiates into fully
differentiated cells is not completely understood, transcription factors play a major role in
determining the specific lineage into which a progenitor will differentiate (29).
Myelopoiesis is the developmental process of producing differentiated cells of the
myeloid lineage, such as monocytes/macrophages, neutrophils, eosinophils, or
basophils/mast cells, from hematopoietic stem cells (HSC). Cells of the myeloid lineage
have various roles in the body and are key mediators in the innate immune system. The
development of cells of the myeloid lineage is tightly controlled by combinations of
transcription factors that control transcription of myeloid specific genes(7, 30-33). Table
1.2 summarizes the structural family, expression pattern and knockout phenotype of
many transcription factors known to be involved in the development of the myeloid
lineage. Some transcription factors particularly important for myeloid development
include PU.l, c/EBPa, and Gfi-1. High levels of PU.l enforce monocyte/macrophage
differentiation at the expense of granulocyte development, whereas high levels of c/EBPa
and Gfi-1 promote granulocyte development.

1.4 Purine-Rich Box 1
Purine-rich box 1, also known as PU.l, is an E26 transformation specific (ETS)
transcription factor essential in the development of myeloid and lymphoid lineages (34).
It was first discovered in 1988 as an oncogene from a proviral insertion of the spleen

II
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Table 1.2 Transcription factors involved in the development of cells in the myeloid
lineage
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Expression
Pattern
B-lymphoid, early
T-lymphoid,
granulocytic and
monocytic cells
B and T cells,
pDCs

Knockout Phenotype

Name

Structural Family

PU.l

ETS family
transcription factor,
helix loop helix protein.

Spi-B

ETS family
transcription factor,
helix loop helix protein.

Spi-C

ETS family
transcription factor,
helix loop helix protein.
CCAAT enhancer
binding protein
(C/EBP) family basic
leucine zipper class
(bZIP) of transcription
factors

B cells and
macrophages

CCAAT enhancer
binding protein
(C/EBP) family basic
leucine zipper class
(bZIP) of transcription
factors
CCAAT enhancer
binding protein
(C/EBP) family
basic leucine zipper
class (bZIP) of
transcription factors
Nuclear zinc finger
transcriptional repressor
containing N-terminal
SNAG domain

Up regulated
during myeloid
differentiation

Granulocytes and
lymphoid cells.

Cebpe'1' mice fail to
generate functional
neutrophils and
eosinophils. (42)

Lymphoid and
granulocytic cells
but not in the
monocyte lineage

Nuclear zinc finger
transcriptional repressor
containing N-terminal
SNAG domain

Highly expressed
in erythroid and
megakaryocytic
precursors, T cells

Gfil'1' display defects in
neutrophil maturation
subsequent to the
promyelocyte stage. (43,
44)
Gfilb'1' mice are
embryonic lethal due to
lack of erythropoiesis. (44)

c/EBPa

c/EBPß

c/EBPs

Gfil

Gfilb

HSC, CMP and
GMP, liver and
adipose tissue

Sfpil'1' mice lack B cells,
monocytes and have
reduced neutrophils. (35)
Spib'1' result in defective T
and B cell responses.
Knockout mice have non
functional B cells.
Spi-B is able to rescue
macrophage and
granulocyte development
in PUT'7’. (36-38)
Spic’' results in fewer red
pulp macrophages. (39)
Cebpa'1' mice lack
neutrophils and
eosinophils and monocytes
and increased numbers of
myeloid blasts in blood
and fetal liver. Loss of the
G-CSF receptor. (40)
Cebpb'' results in reduced
myeloid development. (41)
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MafB

Member of Maf family
of proteins, a subgroup
of AP-l-type bZip
transcription factors

Myeloid lineage of
cells, upregulated
in differentiating
monocytes and
macrophages

Component of AP-1
family of transcription
factors. Contains basic
leucine zipper
EGR family of C2H2 type zinc-finger
proteins

Expression
increases during
monocytic
maturation
Myeloid and
lymphoid cells

Egr-2

EGR family of C2H2 type zinc-finger
proteins

Myeloid and
lymphoid cells

KLF2

Kriippel-like family of
transcription factors.
Contains C2H2 zinc
fingers
Kriippel-like family of
transcription factors.

T cells, B cells,
erythrocytes and
macrophages.

c-Jun

Egr-1

KLF4

PLZF

Kriippel-like family of
transcription factors

Myeloid lineage,
and macrophages

MafB'1' results in
formation of immature
myeloid cells, but cannot
differentiate into F4/80
expressing macrophages.
MafB(D/N) inhibits both
mye- loid colony
formation and the
differentiation of myelo
blasts into macrophages.
Juri ' is embryonic lethal
(E l3.0). Results in
increased levels of
apoptotic cells. (45)
Egrl' ' develops normally,
have increased levels of
dividing HSC. Egrl (D/N)
results in defective
monocyte maturation.
Egrl stimulates monocyte
differentiation in myeloid
cell lines and murine
marrow progenitors at the
expense of granulopoiesis.
(46, 47)
Functions redundantly
with Egr2 to promote
monocyte differentiation.
(46)
Klf2' ' is embryonic lethal,
due to defective
erythropoeisis.
/

K l ff' is lethal. KLF41oxP
models demonstrate a
reduction in mature
monocytes and an increase
in granulocyte formation.
(48)
LT-HSC, erythroid, Zbtbl6' ' knockdown
results in increased
monocyte, and
number of granulocytes.
granulocyte
progenitors. Not in Important in development
differentiated cells. of megakaryocytes and
NKT cells lineages.
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Evil

SET/PR domain family
of transcription factors

Mef2c

Myocyte enhancer
factor 2 (Mef2) family
of MADS-box
transcription factors

RARa

NHR/NR1 Thyroid
hormone-like

HoxAlO

Homeobox gene family

Runxl

Runt-related
transcription factor
(RUNX) family. Also
called core binding
factor-a (CBFa)

c-Myc

Myc family of
transcription factors.
Basic helix-loop-helix
(HLH) leucine zipper
protein

c-Myb

MYB family of
transcription factor

Mecom'1' is embryonic
Expression is
limited to HSC and lethal. (Blocks
progenitors. Evil is granulocytic
differentiation in myeloid
essential for the
cells). (49)
maintenance of
HSCs, dispensable
for blood cell
lineage
commitment.
Mef2c'' absense from
B cells, myeloid
hematopoetic progenitors
cells
results in deficiency in
lymphoid development
and enhanced myeloid
development. (50)
Myeloid lineage
Rara(DfN) results arrests
granulopoiesis at the
cells
promyelocyte stage. (51)
Immature myeloid HoxalO'1' show an increase
in increase in peripheral
cells
blood neutrophils and
monocytes.
All hematopoetic
Runxl'1' results in lack of
lineages
hematopoesis. Conditional
knockouts result in
impared megakaryocyte
maturation. Defective T
and B cell development
and myeloid proliferation.
(52)
All proliferating
Myc ' mice embryonic
cells. Repressed in lethal between E9.5 and
terminally
10. Conditional knockout
differentiated cells. leads to increased HSC,
and reduced
differentiation. (53)
c-Myb expression
Myb'1' mice embryonic
is largely restricted lethal by E l5.5; fetal liver
to progenitor cells
contains drastically
and downregulated reduced numbers of
in differentiating
hematopoietic progenitors,
cells.
and lack of erythroid and
myeloid cells. (54)
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c-Myb
(cont.)

IRF4

Interferon regulatory
factor family of
transcription factors

IRF8

Interferon regulatory
factor family of
transcription factors

TFEC

Microphthalmia-TFE
(MiT) subfamily of
basic helix-loop-helix
(bHLH) transcription
factors
Microphthalmia-TFE
(MiT) subfamily of
basic helix-loop-helix
(bHLH) transcription
factors
Helix-loop-helix
(HLH) family of
transcription factors

MITF

Idl

Id2

Helix-loop-helix
(HLH) family of
transcription factors

Overexpression
inhibits erythroid
and myeloid
lineages. Can be
expressed in
activated T and B
cells.
T and B cells.
Upregulated during
myeloid
differentiation
IRF8 expression
occurs in
macrophages,
dendritic cells, B
cells and stimulated
T cells
Myeloid lineage
cells

Irf4 results in B and T
cells maturation
deficiencies.
IrfS’1' results in abnormal
neutrophil maturation,
block in eosinophil
development and defective
macrophage function.
Tcfec'~ has no phenotype
despite being cell specific.
May be redundant with
other family members.

Osteoclasts and
mast cells

Mitf'~ results in severe
reductions in osteoclasts,
mast cells and NK cells.
(55)

Myeloid
progenitors and
mature
macrophages,
decreased during
neutrophil
differentiation.
Differentiating
DCs

Id l'1'have increased
monocytes and
granulocytes.
Lymphocytes and platelet
numbers are decreased.

I d l 1' results in loss of
mature T cells, reduction
in DC levels.
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focus forming virus (SFFV), which resulted in erythroleukemia. The gene is named
SFFV proviral integration site-1 (Spi-1) in humans and Sfpil in mice (56). PU.l is a 42
kilodalton (kDa) protein encoded by the gene Sfpil whose primary isoform is composed
of 212 amino acids (57). The human homologue is quite similar showing 85% amino acid
homology with mouse PU.l (58, 59).
PU.l contains three major functional domains: a C-terminal DNA binding
domain, a PEST domain and an N-terminal transactivation domain (60). As with all ETS
family transcription factors, PU.l contains a highly conserved helix-turn-helix DNA
binding domain which is located within the C-terminal 100 amino acids (61). It binds to a
10 base pair segment of double stranded DNA, which requires the consensus core
sequence “GGAA” or “AGAA”. In addition to DNA binding, the ETS domain is able to
interact with a number of accessory proteins such as c-Jun, c/EBPa, and GATA-1, among
others (62-64) (Figure 1.3). The N-terminal transactivation domain consists of three
acidic amino acid rich regions and one gluatamine rich region. This region also allows for
direct interaction with other proteins such as TFIID, TBP, among others (Figure 1.3).
Finally, the PEST domain is located between the transactivation domain and the ETS
domain. This domain gets its name as an acronym, which stands for Proline (P), Glutamic
Acid (E), Serine (S), and Threonine (T). This domain is typically involved in protein
stability/degradation (65) but is also involved in protein-protein interactions with IRF-4
and IRF-8 (66, 67)(Figure 1.3).

1.5 The expression and regulation of PU.l in myeloid development.
The expression of PU.l is limited to the hematopoietic system. PU.l is an
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Figure 1.3 Protein-protein interactions involving PU.l
The transcription factor PU.l shown in red contains 3 domains: An N-terminal
transactivation domain, a PEST domain, and a C-terminal ETS domain. The named
proteins have been shown to directly interact with PU. 1 within the corresponding domain.
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P E S T D o m a in
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GATA-1
GATA-2
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GATA-2
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essential transcription factor in hematopoiesis, particularly in myeloid development. PU. 1
is expressed at low levels in HSCs, and in the early progenitor cells CMPs and CLPs (68,
69). Expression levels of PU.l increase dramatically during terminal myeloid
development; they are decreased during terminal B cell development and shut off during
terminal erythrocyte/megakaryocyte development (68-70). PU.l also gets shut off during
T cell differentiation, however there are certain subsets of T cells that re-express PU. 1
during terminal differentiation (71).
At all times, the gene encoding PU.l is tightly regulated due the importance of
correct time and location of PU. 1 expression. Many groups have shown that incorrect
expression of PU.l will lead to abnormal development of the hematopoietic system and
may result in leukemia (72). The PU. 1 promoter region contains several binding sites for
transcription factors that regulate the gene. These include an Octamer (Oct-1) site 54 bp
upstream of the transcription start site (TSS), an Spl site 39bp upstream of the TSS, a
PU.l site 20bp 3’ of the TSS and a GATA binding site 15bp upstream of the TSS (56, 73,
74). All of these transcription factors are expressed in HSC, and may initiate
differentiation. It has also been discovered that there is an upstream regulatory element
(URE), which is 14kb upstream of the TSS (75). Deletion of the URE downregulated the
expression of PU.l to approximately 20% of wild-type levels in myeloid cells (76). PU.l
may be able to direct its own expression through the URE as well as the binding site
within the PU.l promoter. RUNX1, also known as AML1, is another important regulator
of PU.l. It has been shown to regulate PU.l in a lineage specific positive and negative
manner in the promoter and URE regulatory regions (77). In addition to these
transcription factors, PU.l is targeted and upregulated by the Notchl signaling
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pathway(78).

1.6 The role of PU.l during myeloid development
PU.l is essential for the development of cells in the myeloid lineage. This has
been shown through many mouse models where PU.l has either been knocked-out,
knocked-in, over expressed or restored. There have been two labs that have created an
Sfpil'/' mouse. The first group, lead by Dr. Harinder Singh, generated the SfpiT1'mouse
by knocking out the ETS DNA domain and replacing it with a neomycin resistance gene
(79). The second group, lead by Dr. Richard Maki, generated their Sfpil'^mouse by
knocking in a neomycin resistance gene into the ETS domain (34). The Sfpil'A mouse
generated by the Singh group was embryonic lethal by 18.5 d.p.c and contained no
detectable myelopoiesis, whereas the Sfpil'1' mice generated by the Maki group survived
for 2 days after birth, at which point they die due to septicemia. However, it was possible
to keep these mice alive for up to 2 weeks using antibiotics. With this treatment, there
were a small number of neutrophils generated. It is interesting that in the heterozygous
S$?z7+/'mice that express PU.l at 50% of normal levels, the phenotype is relatively
normal. These mice have myeloid cells that are functionally normal. These two studies
agree that in the absence of PU.l there are severe defects in myelopoiesis.
While the PU.l mutants show a portion of the story, other mouse models have
shown that PU. 1 functions in a dose dependant manner in the myeloid lineage. A group
led by Dr. Daniel Tenen generated a mouse model with a deletion in the upstream
regulatory enhancer (URE), which is 14kb upstream of the transcription start site (76,
80). When this region was deleted, the mice had reduced expression of PU.l to 20% of
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wild-type levels in most tissues with the exception of T cells where it was upregulated.
This resulted in impaired myeloid differentiation and acute myeloid leukemia, suggesting
an increase in proliferation, as well as a block in B cell development.
Our lab developed an alternate mouse model where PU.l is reduced in all cell
types to 20% of wild-type levels (27, 81). This was performed by insertion of a Blactamase gene and neomycin resistance cassette into the first exon of PU.l, which
resulted in this allele of Sfpil being named “BN”. SfpilBN alleles of PU.l are transcribed
and translated at a 3rd start codon instead of its normal start site, which results in PU.l
being truncated by 31 amino acids at the N-terminus. Due to altered transcriptional
regulation, it also results in the protein being expressed at 20% of wild-type levels. The
protein itself is fully functional. Mice that are homozygous for this allele (SfpilBN/BN)
display a severe phenotype. While they are viable, they do not survive past weaning (21
days after birth). They are runted, osteopetrotic, and display a macrophage and B cell
deficiency (27). Based on these mouse models, it appears that PU.l expression below
20% of wild-type levels result in severe myelopoiesis defects. This suggests PU.l
functions in a dose-dependent manner, and levels at or below 20% are insufficient to
promote normal myeloid or B cell development.

1.7 Transcriptional targets of PU.l
PU.l has been shown to have binding sites in many myeloid promoters (33). PU.l
has been shown to regulate genes encoding granulocyte colony stimulating factor
receptor (GCSFR) (82), macrophage colony stimulating factor receptor (MCSFR) (83),
and the granulocyte-macrophage colony stimulating factor receptor (GMCSFR) (84).

23

These genes encode receptors for growth factors, which are essential for the proliferation
and differentiation of cells of the myeloid lineage. In addition to regulating growth
factors receptors, PU.l activates genes required for a myeloid phenotype. This includes
the adhesion molecule CD lib (85), which is a marker of a differentiated macrophage.
PU.l also activates CD 18 (86) which together with C D llb forms the complex Mac-1.
PU.l also activates FcyRI (87) and FcyRIIIA (88), which are receptors for the constant
region of immunoglobulin G (IgG), as well as scavenger receptors type I and II, which
are involved in the innate immune system responses (89). Furthermore, recent studies
have shown that PU. 1 is directly involved in the regulation of a large portion of genes
involved in inflammation including interleukin-1 beta (IL-113), secretory IL-1 antagonist,
IL-18, IL12p40 subunit and tumor necrosis factor (TNF)(90). Based on the function of
the type of the genes that are targeted by PU.l, it is understandable that loss or
downregulation of PU.l will result in the lack of differentiated or functional
differentiated myeloid cells.

1.8 The Role of PU.l in skeletal development
There are two forms of skeletal development. The first is intramembranous bone
formation, during which mesenchymal cells condense and directly differentiate into
osteoblasts to deposit bone matrix (91). This form of skeletal development occurs in the
flat bones such as seen in the skull. While this is a straightforward process, it is seen as
the exception in bone development. The second form of skeletal development is
endochondral bone formation which begins when mesenchymal cells form condensations,
which become chondrocytes (92). Chondrocytes are cells that reside in the growth plate
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and contribute to the longitudinal growth of bones (93). The innermost chondrocytes
enlarge by proliferating to first form the pre-hypertrophic zone and the hypertrophic
chondrocytes, which begin to express the cell cycle inhibitor p57. P57 arrests
hypertrophic cells in the G1 phase of the cell cycle and is a marker of hypertrophic
chondrocytes in the growth plate (94). Hypertropic chondrocyte secrete an extracellular
matrix (ECM) that is rich in collagen, which promotes vascularization. Once this is
complete, chondrocytes undergo apoptotic death. The ECM is invaded by osteoblasts and
osteoclasts, which results in bone formation and remodeling. The ECM that is left behind
provides a scaffold that the osteoblasts and osteoclasts may remodel and lay down new
bone matrix.
Osteoclasts are derived from cells of hematopoietic origin and are from the
myeloid lineage (95-97). The main function of the osteoclast is bone resorption, which is
necessary during bone growth, tooth eruption, and fracture healing. Osteopetrosis is a
bone disease that is characterized by lack of osteoclast function and results in increased
bone mass and a loss of the bone marrow cavity. Osteoclasts are identified by their
expression of tartrate-resistant acid phosphatase (TRAP)(98, 99). Osteoclast activity is
enhanced by several factors such as IL-1 (100), M-CSF (100-102), TGF-a (103) ,
TNFa/13 (103), IL-6 (104), and IL-11 (105). PU.l is essential for the development of
osteoclasts since it controls the expression of these factors such as IL-1 and M-CSF.

1.9 Cell Cycle Regulation
The cell cycle is the process by which DNA is replicated and segregated into two
separate daughter cells. The process is divided into four stages: the Gi phase, where the
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cell grows in size and prepares for DNA synthesis; the S phase, where the cell undergoes
DNA replication; the G2 phase, where the cell prepares for mitosis and the M phase
where cell undergoes mitosis (106). Cells may also enter into Go phase before G| which
is when cells become quiescent and stop proliferating. Two families of proteins control
the cell cycle: the cyclin dependant kinases (CDKs) and cyclins. CDKs are
serine/threonine kinases which are activated during particular points in the cell cycle and
phosphorylate downstream proteins which leads to cell cycle progression (107). The
amount of CDKs remains stable during the cell cycle, but their state of activation
fluctuates depending on the particular CDK and the stage of the cell. Cyclins regulate
CDK function by physically interacting with CDKs and activating them (107). Cyclin
levels constantly fluctuate during the cell cycle. CDKs can be inhibited by cyclin
dependant kinase inhibitors (CKIs) that can bind CDKs alone or in their CDK/cyclin
complexes. There are 2 main families of CKIs: the INK4 family and the Cip/Kip family
(108). Both of these families of inhibitors tend to inhibit the Gl-S phase checkpoint of
the cell cycle. One major target that the CDK/cyclin complexes target is retinoblastoma
protein (Rb) and E2F1 (109). Once the CDK/cyclin complex phosphorylates Rb, it
dissociates from E2F1 and allows E2F1 to activate target genes important in the Gl- S
phase checkpoint. E2F1 has been studied extensively in its role in the cell cycle. It has
been shown that ectopic expression of E2F1 alone can drive Gl arrested cells into S
phase allowing for cell cycle progression (110-112). Furthermore, dominant-negative
forms of E2F1 arrest cells during the Gl phase of the cell cycle (113). In summary, the
cell cycle is a tightly coordinated process regulated in both a positive and negative
manner, and dysregulation may lead to oncogeneisis.
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1.10 PU.l and Acute Myeloid Leukemia
PU.l is an essential transcription factor in the development of the hematopoietic
system, particularly in the myeloid lineage. Therefore it is important to study the effects
that deregulation of PU.l can cause in leukemia since PU.l has been shown to be
involved in human cases of AML. One study showed that PU.l was mutated in 7% of
patients with AML (114). In mouse models, down-regulating PU.l was sufficient to
cause AML in the absence other mutations (76). Dr. Tenen’s mouse model of reduced
PU.l develop AML at an average age of 3 months, and die by 9 months from an
aggressive form of AML. The SfpilBN mouse model with reduced PU. 1 also appears to
have a dramatic expansion of immature myeloid cells after birth. These mice have an
expansion of immature myeloid cells and do not survive past weaning, however it is
unknown whether the cause of death is leukemia or due to the osteopetrosis they also
develop. These results show the importance of PU. 1 in the development of AML and the
need to further understand the mechanism by which PU. 1 causes the differentiation block
that leads to AML.
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1.11 Hypothesis and Objectives
Acute Myeloid Leukemia is a type of cancer in which myeloid progenitors have
retained their ability to self-renew and are unable to differentiate. Many subtypes of AML
are characterized by mutations in genes encoding transcription factors that regulate
differentiation, and PU.l has been implicated in the development of AML in both
humans and in mouse models. Furthermore, PU.l regulates many genes involved in
myeloid development. If PU.l regulated a gene involved in differentiation through the
control of the cell cycle, dysregulation may lead to increased proliferation, lack of
differentiation and development of AML. Therefore, I hypothesize that reduced levels
of PU.l cause AML by promoting self-renewal of myeloid progenitors through
deregulation of the cell cycle, which results in increased proliferation and a block in
terminal differentiation; where I define self-renewal as an increase in cell division in
the absence of differentiation.
To test this hypothesis, the following objectives were performed:
1. The first objective is to characterize the SfpilBN/BMmouse phenotype to determine if
there is increased proliferation and unregulated cell cycle in the myeloid lineage.
2. The second objective is to determine whether a reduction in PU.l leads to
increased self-renewal.
3. The third objective is to determine the mechanism by which PU.l is controlling
proliferation.
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CHAPTER 2: MATERIALS AND METHODS
2.1 Mouse Strains
Mice were housed in the University of Western Ontario Health Sciences animal
facility (London, Ontario, Canada). Animal husbandry and breeding was done in
compliance with animal protocols approved by the University of Western Ontario
University Council on Animal Care. C57BL/6 mice were purchased as required from
Charles River Laboratories (Pointe-Claire, Quebec, Canada). Sfpil+/BN mice were
previously generated and maintained as an SJpil+/BN colony(81). Sfpil+/BN were
genotyped by PCR using primers found in table 2.1. Sfpil+/BNmice were mated to obtain
SfpilBN/BN neonates. Embryonic day 14.5 (E14.5) fetuses were generated by performing
timed matings of Sfpil+/BNmice. At E14.5, pregnant mothers were euthanized and fetuses
were collected by dissection and phenotyped by expression of C D llb in the fetal liver.
CD1 lb expression levels are highest in Sfpil+/+ mice, intermediate in Sfpi 1+/BNmice and
low in SfpilBN/BNmice. These results were later confirmed by PCR genotyping.

2.2 Cell Culture
All

complete

media

contained

10%

fetal

bovine

serum,

100

U/mL

penicillin/streptomycin, 2 mM L-glutamine, 5 xlO'5 M 2-mercaptoethanol, and 0.5 mM
HEPES (HyClone, Logan, UT, USA). Platinum-E (Plat-E) retroviral packaging cells
were grown in Dulbecco's Modified Eagle Medium (DMEM) media. NIH3T3 cells were
grown in DMEM media. SfpiBN/BN cells were grown in Iscove's Modified Dulbecco's
Media (IMDM) medium containing 2 pg/mL GM-CSF. All complete media contained
10% fetal bovine serum, 100 U/ mL penicillin/streptomycin, 2 mM L-glutamine, 5 xlO'5
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Tahle 2.1 PCR and RT-aPCR primer sequences

Primer Name
Sfpil Primer 1
Sfpil Primer 2
Sfpil Primer 3
Sfpil Primer 4
ckit Right
ckit left
p i 5 left (2)
p i 5 right (2)
ki67 left
ki67 right
p i 5 right (1)
p i 5 left (1)
p i 6 left
p i 6 right
p27 right
p27 left
p21 right
p21 left
cdknlc right
cdknlc left
Rbl right
Rbl left
e2fl right
e2fl left
e2f2 right
e2f2 left
e2p right
e2 p left
Cdk6 right
Cdk6 left
Tyms right
Tyms left
PolAl right
PolAl left
cMyc right
cMyc left
c/EBPa right
c/EBPa left
skp2 right
skp2 left
miR-223 left
miR-223 right

Sequence
5’ CGGCCAGAGACTTCCTGTAG-3’
5 ’-AAGTTGGCCGCAGTGTTATC-3 ’
5’-GCTCTTCGTCCAGATCATCC-3’
5’-ATGGTCACACATCCCAAAGC-3 ’
5'-TGTCGCCAGCTTCAACTATT-3'
5'-GATCTGCTCTGCGTCCTG-3'
5'-ATCCCAACGCCCTGAAC-3'
5'-TCGTGCACAGGTCTGGTAAG-3'
5'-GTCCACCTGGTCACCATCAA-3'
5'-TT GACACTACAGGCAGCTGGATAC-3'
5'-CAGTTGGGTTCTGCTCCGT-3'
5'-AGATCCCAACGCCCTGAAC-3'
5'-GCAGAAGAGCTGCTACGTGA-3'
5'-CGTGAACATGTTGTTGAGGC- 3'
5'-TCTGTTGGCCCTTTTGTTTT-3'
5'-GGGTCTCAGGCAAACTCTGA-3'
5 AGAGACAACGGCACACTTT G-3'
5'-CGGTGTCAGAGTCTAGGGGA-3'
5'-GTTTGGAGAGGGACACCCTG-3'
5'-CTGAAGGACCAGCCTCTCTC-3'
5'-CCATGATTCGATGCTCACAT-3'
5'-ACAGATTTGTCCTTCCCGTG-3'
5'-CAGCGAGGTACTGATGGTCA-3'
5'-CGATTCTGACGTGCTGCTC-3'
5' -GAAGAGGGTGTGACAGCTCC- 3'
5'-GGGAT CGCAGAGACCATAGA-3'
5' -TAATGGGGTTTCTGTCTGGG-3'
5'-TGAAGATGCAGAGAACGCAC-3'
5'-CTTGGTTTCTCTGTCCGTCC-3'
5 AGT GCAGACCAGTAGGAGG-3'
5'-CTGGTCTACTCCTTGTCCCG-3'
5'-TTTCTGGACAGCTTGGGATT-3'
5'-GCCACTCCAGGACAAGAACT-3'
5' -CATTTTTGATGCGGACT GTG-3'
5'-TGAGCCCCTAGT GCTGCAT-3'
5'-AGCCCGACTCCGACCTCTT-3'
5 AGCCAAGAAGTCGGTGGACAAGAA- 3'
5'-GCGGTCATTGTCACTGGTCAACTC-3'
5' -GAGGT GGACAGTGAGAACATC-3'
5'-AGGAAAAGATCCCAAGGAGC-3'
5'-CCGTGTATTTGACAAGCTGAGT-3'
5'-TGGGGTATTT GACAAACTGACA-3'
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M 2-mercaptoethanol, and 0.5 mM HEPES (HyClone, Logan, UT, USA)

2.3 Retroviral Production
Previous members of our lab constructed the MigRl, MigPU.l and LMP-PU.1-1
retroviruses. MigRl stands for Murine (MSCV) IRES GFP EcoRl. MigPU.l is a
retroviral vector with a 3x-FLAG tagged PU.l cDNA cloned into the multiple cloning
site and is constitutively expressed. LMP-PU.1-1 is a retroviral vector containing a
miRNA against PU.l that is able to knockdown PU.l expression. Platinum-E (Plat-E)
retroviral packaging cells(l 15) were used to generate retroviral supernatants using
polyethelenimine (PEI) transfection. Twenty four hours before transfection, Plat-E cells
were plated at a concentration of 5xl06 cells in a 10cm dish. One mL of serum-free
DMEM, 10 pg of plasmid DNA, 2.5 pg of packaging DNA were mixed. Samples were
vortexed and 21 pg of PEI was added and incubated for 15 minutes at room temperature
without disturbance. One ml of the DNA/PEI mixture was added to the cells with lmL of
complete DMEM. Transfected cells were incubated overnight. Media was then replaced
with 2ml complete DMEM. Virus containing supernatants were collected at 48 hours post
transfection. Virus titers were measured by flow cytometry by infection of NIH-3T3 cell.
NIH-3T3 cells were plated at 200,000 cells per well in 6 well plate and incubated
overnight. Next, serial dilutions of retroviral supernatent were given to NIH-3T3 cells
and polybrene was added to an 8 pg/ml final concentration. Cells were then incubated for
4 hours after which media was replaced with fresh DMEM. Cells were then incubated for
48 hours after which they were analyzed for green fluorescent protein (GFP) expression
by flow cytometry. Titers were calculated by percentage of infected cells multiplied by
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400000 cells, under the assumption of 1 doubling before infection, and multiplied by
dilution factor of retroviral supernatant.

2.4 Lineage Depletion and Retroviral Infection
Lineage depletions were performed using a MACs Lineage Cell Depletion Kit.
Cells were incubated in 200 ml MACS buffer containing the following anti-Lin
antibodies: biotin a-CD4 (HI29.19), a-CD5 (53-7.3), a-CD8a (53-6.7), a-CD3e (1452C11), a-Gr-1 (RBC-8C5), a-Terll9 (Terll9), a-B220 (RA3-6B2). Following
incubation 10 ml streptavidin-microbeads (Miltenyi Biotec, Auburn, CA) were added and
passed through a VarioMacs column. Lineage negative cells were then centrifuged for 6
minutes at 1500 rpm and pellet was used for infection. For retroviral infection, lineage
depleted fetal liver progenitors or GM-CSF SfpiBN/BN cells were infected by resuspension
in cell- free retroviral supernatants and centrifuged at 2000g for 3 hours in the presence
of polybrene to 8-pg/ml final concentration. Following centrifugation, hematopoietic
progenitors were washed and stimulated for 2 days in complete IMDM containing 100
ng/mL murine stem cell factor, 10 ng/mL mIL-3, and 10 ng/mL mIL-6 and incubated at
37°C (Peprotech, Rocky Hill, NJ, USA). Infection frequencies were detected by flow
cytometric analysis for GFP.

2.5 Immunoblotting
Proteins

from whole

cell

lysates

were

resolved

by

SDS-PAGE

and

electrotransferred to a nitrocellulose membrane (Pierce). Immunoblotting was performed
with rabbit anti-PU.l polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA,
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USA), HRP-conjugated anti-FLAG antibody (Sigma, St. Louis, MO, USA), goat
polyclonal anti-ß-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), HRPconjugated anti-rabbit secondary antibody (Pierce, Rockford, IL, USA) and HRPconjugated anti-goat secondary antibody. Immunoreactive proteins were visualized with
SuperSignal West Pico reagent (Thermo-Fisher Scientific, Waltham, MA, USA)

2.6 Flow Cytometry
Flow-cytometric analysis was performed on single-cell suspensions of cells washed
in phosphate-buffered saline (PBS) containing 0.05 M EDTA and 0.5% BSA. Cells were
analyzed on a FACSCalibur (BD, Franklin Lakes, NJ, USA). Propidium iodide uptake
and side light scatter gating for cell size were used to exclude dead cells from analysis.
Cell cycle analysis was performed using propidium iodide staining as previously
described(116). Antibodies used were biotin-conjugated monoclonal antibody Ml/70
(CDllb), RB6-8C5 (Ly-6C, Gr-1), 2B8 (CD117, c-Kit), streptavidin-allophycocyanin
conjugate, streptavidin-phycoerythrin conjugate, streptavidin-Fluorescein isothiocyanate
conjugate (BD Pharmingen, Franklin Lakes, NJ, USA). A minimum of 20,000 cells were
collected for analysis. Analysis was performed using FlowJo version 9.3.2 (Ashland, OR)
or ModFit LT (Topsham, ME).

2.7 Real-Time quantitative PCR (RT-qPCR)
RNA was isolated from cells using RNA Bee RNA Isolation Agent (Tel-Test,
Friendswood, Texas) and reverse-transcribed into cDNA using the iScript DNA synthesis
kit (Bio-Rad, Hercules, CA). Quantitative PCR (qPCR) was performed using the iQ
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SYBR Green Supermix kit (Bio-Rad) and a Rotor-Gene 6000 instrument (Corbett Life
Sciences, Valencia, CA). Relative mRNA transcript levels were normalized to GAPDH
as a reference gene and compared between samples using the comparative threshold cycle
method (117). Results are presented as the mean and SD of triplicate experiments. Primer
sequences are listed in Supplemental Table 2.1.

2.8 Immunofluorescence staining
Spleens were embedded in Tissue-Tek OCT compound (Sakura-Finetec, Torrance,
CA) and frozen in liquid nitrogen. Spleen sections cut at 5 pm were fixed in 4%
paraformaldehyde and blocked with 5% BSA. After blocking, the sections were
incubated with primary anti-mouse Ki67-Alexafluor 488 antibody (B56; BD Biosciences,
San Diego, CA) and biotin-conjugated monoclonal antibody Ml/70 (CDllb) with a
streptavidin-phycoerythrin conjugate. Sections were mounted in Vestashield mounting
medium (Vector Labs, Burlingame, CA) and photographed with a Nikon (Melville, NY)
Eclipse 80i microscope attached to an X-cite 120 fluorescence illumination unit.

2.9 Colony Forming Assays
Spleens were removed from neonatal SfpilBN/BN, Sfpil+/BN or Sfpil+/+ mice and
homogenized. Following homogenization, cells were phenotyped by determining CDllb
levels by flow cytometric analysis. 50000 cells were then placed in 3.5cm tissue culture
dishes with MethoCult (M3234) methylcellulose medium (Stem Cell Technologies,
Vancouver, BC, Canada) containing recombinant murine granulocyte macrophage
colony-stimulating factor (GM-CSF; 1 ng/mL), IL-3 (5 ng/mL) IL-6 (10 ng/mL), SCF
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Figure 2.1 Schematic of colony forming assay.
Timed matings are performed to collected E14.5 fetal livers from Sfpil+/+, Sfpil+/BNand
SfpilBN/BN mice. Fetal liver cells are then phenotyped then placed in methylcellulose
media, which contains differentiating cytokines (GMCSF or IL3/IL6/SCF). These are
then incubated for 1 week without disturbance. After incubation, colonies are counted
under a microscope after which cells are collected, washed and replated in methocult for
a following week. Assay continues until colony formation stops, or at a predetermined
timepoint.
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(100 ng/mL) (Peprotech) (Figure 2.1). Cells were then incubated for 1 week at 37°C
without disturbance. Colonies were counted using a Zeiss Axio observer inverted
fluorescent microscope (Zeiss, Gottingen, Germany), where a colony consists of a
minimum of 50 cells. Cells were collected, washed 3 times in PBS and replated in
methylcellulose as described above. Assays were repeated for as long as colonies were
formed or were ended after a 10-week period.

2.10 Skeletal Staining with Alzarin Red and Alcain Blue
Skeletons were isolated by dissection and dehydrated in 95% ethanol for 24 h,
followed by acetone for 24 h. Skeletons were then stained with 0.015% alcian blue,
0.05% alizarin red, and 5% acetic acid in 70% ethanol. Samples were transferred to 2%
Potassium Hydroxide and kept in solution on a rocker overnight. They were then replaced
with 1% Potassium Hydroxide, and maintained on the rocker until bones were fairly
clean of tissue. The samples were checked daily to prevent over digestion. Afterwards
bones were carefully debrided under a dissecting microscope using fine forceps.
Afterwards samples were stored in a 1:1 solution of 70% ethanol: glycerol.

2.11 TRAP staining and Immunohistochemistry
Limbs were dissected away from torso using tweezers and placed in PSA (modified
PBS) on ice. Bones were fixed overnight in 4% paraformaldehyde at room temperature
with rocking. Older mice required décalcification of long bones prior to transferring into
70% ethanol. P21 mice required 5-7 days to decalcify adequately.

Bones were

decalcified in 5% EDTA solution pH7.0 in PBS. Solution was changed every 2-3 days
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until the bones were decalcified. Decalcified bones were transferred into 70% ethanol at
4°C and stored until sectioning. All sectioning was performed by the molecular pathology
core facility (Robart’s Research Institute, London, ON, Canada). Samples were paraffin
embedded and sectioned at a 5-pm thickness and placed on a glass coverslip.
For TRAP stain, a Leukocyte Acid Phosphatase kit was used (Sigma-Aldrich,
Oakville, ON). Paraffin embedded samples were rehydrated by the following protocol: 1.
Washed in xylene for 5 minutes, second wash in xylene for 8 minutes, then washed in
100% ethanol, 95% ethanol, 70% ethanol for 2 minutes each wash, then washed twice in
water for 5 minutes, then washed twice in PBS for 5 minutes. After rehydration samples
were washed in Triton x-100 (0.1% in H2 O) for 15 minutes, then washed twice in PBS for
5 minutes. Samples were then stained with TRAP stain mixture following the
manufacturer’s instructions overnight at 4°C. After the staining, cells were washed twice
with PBS for 5 minutes, then rinsed with H2 O and mounted with vectashield mounting
solution (Vector Laboratories, Burlingame, CA, USA).
For p57 immunohistochemistry (IHC), samples were first embedded in paraffin and
rehydrated as described above, followed by washing in PBS, blocking in 3% H2 O2 in
methanol for 15 minutes and then washed in H2 O for 5 minutes. Antigen retrieval was
performed by placing samples in Triton x-100 (0.1% in H2 O) for 13 minutes and then
washing in H2 O for 5 minutes. Slides were blocked with goat serum using a 1:20 dilution
in PBS, 100 pL per slide. A 1:200 dilution of primary p57 antibody in blocking buffer
(Santa Cruz #Sc-8282) was incubated on the slide overnight at 4°C, 100 pL per slide.
After incubation samples were washed 4 times with PBS. Samples were then incubated
for 1 hour at room temperature with a 1:200 dilution of secondary horseradish peroxidase
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(HRP) goat anti-rabbit antibody. After incubation samples were washed in H2 O for 5
minutes and then stained with 3,3'-diaminobenzidine tetrahydrochloride (DAB) which
reacts with HRP to stain areas detected by the primary antibody. After staining, cells
were washed in H2 O for 2 minutes are counterstained with methyl green for five minutes
and mounted in aqueous mounting media(Dako).

2.12 Statistical Analysis
Statistical significance was determined by unpaired or paired Student's t-test
or ANOVA using GraphPad Prism v.6. Differences were considered significant with a Pvalue <0.05.
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CHAPTER 3: RESULTS
3.1 Reduction of PU.l levels result in increased mveloproliferation in vivo
n \

Our lab developed a mouse model where an allele for PU.l named Sfpil

t

has

reduced expression of PU.l in all cell types to 20% of wild-type levels (81). SjpilBN/BN
mice are bom but do not survive past weaning. Neonatal SfpilBN/BNmice were previously
reported to be runted, osteopetrotic, but with increased spleen size. SfpilBN/BNmice were
obtained by mating Sfpil+/BN breeding pairs. It was confirmed that SfpilBN/BN mice were
runted, and osteopetrotic compared to Sfpil+/+ and S fp il>/BN littermate controls (Figure
3.1 A, osteopetrotic data shown in upcoming section). Western blot of whole spleen lysate
using anti-PU.l antibodies confirmed that PU.l was reduced in SfpilBN/BNmice compared
to littermate controls (Figure 3.IB). Furthermore, the spleens of SfpilBN/BNmice were pale
compared to littermate controls, which suggests an altered cellular composition (Figure
3.1C).
To determine whether the composition of cells was altered in the spleen, flow
cytometric analysis was performed for CD lib, Gr-1 and c-Kit. CD lib and Gr-1 were
both chosen since they are markers of the myeloid lineage expressed on the cell surface.
c-Kit was also chosen because it is expressed on immature myeloid progenitors (118).
Flow cytometric analysis of SfpilBN/BN spleens determined that there was a significant
increase in the frequency of immature myeloid lineage cells compared to littermate
controls, as seen through an increase in the percentage of CD1 lb+, c-Kit+ cells or Gr-1+,
c-Kit+cells (Fig.3.2 A, B). These results suggested that myeloid proliferation is altered in
the spleens of these mice.
To confirm that proliferation was occurring, RT-qPCR was performed to measure
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Figure 3.1 SfvilBN/BNmice are runted and present with a pale spleen.
(A) 21 day old SfpilBN/BN mice were runted compared to their littermates. An image
of SfpilBN/BN and Sfpil+/+ littermates side by side showing the runted phenotype of the
SfpilBN/BN mice.

(B) Spleens from SfpilBN/BN mice are pale compared to Sfpil+/+

littermates. In the upper panel, the arrow points towards spleen of an Sfpil+/+ mouse. In
the lower panel, the arrow points towards spleen of an SfpilBN/BN mouse. Representative
images of results from 3 separate experiments. (C) Construction of the SfpilBN
hypomorphic allele. The Sfpil

DAT

hypomorphic allele was constructed by inserting B-

Lactamase and an inverted PGK-neomycin resistance cassette in to the first exon of PU.l.
Image not to scale.
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Figure 3.2 SfpilBN/BN mouse spleens contain an increased population of immature
myeloid cells.
(A) Gating Strategy for Flow cytometric analysis of spleen cells. Cells were gated to
exclude dead cells from analysis (B) Flow cytometric analysis of the spleens of
SfpilBN/BN mice shows a significantly increased population of immature myeloid
lineage cells. The upper panels show dot plots of C D llb vs. c-Kit whereas the lower
panels show dot plots of Gr-1 vs. c-Kit. The left panels show results from Sfpil+/+ mice
whereas the right panels show results from SfpilBN/BN mice. Representative dot plot from
3 separate experiments. (B) Immature myeloid lineage cells are significantly increased
in SfpilBN/BN spleens. A bar graph shows the statistically significant difference between
CD llb vs. c-Kit and Gr-1 vs. c-Kit in Sfpil+/+vs. SfpilBN/BN mice. Significance was
determined by students T-test (n=3).
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Ki-67 transcript levels. Ki-67 is a nuclear protein necessary for cellular proliferation,
which is present during active cell cycle but absent from resting cells (119). RT-qPCR
performed on Ki-67 showed the transcript is significantly increased (3-fold) in SfpilBN/BN
spleens compared to Sfpil+/+ littermates (Figure 3.3A). CD1 lb and c-Kit transcripts were
also upregulated in SfpilBN/BN spleens, serving as positive controls. To confirm that the
Ki-67 protein was being expressed and that it was upregulated, we performed
immunofluorescent staining on frozen sections of SfpilBN/BN spleen. Ki-67 protein was
increased in the spleens of SfpilBN/BN mice compared to littermate controls (Fig 3.3).
These results indicate that there is increased proliferation in the spleens of SfpilBN/BN
mice.
Since there was an increase in proliferation in the spleens of SjpilBN/BNmice it was
important to determine whether the cell cycle status was altered in these cells, and at what
stage the cell cycle was unregulated. Propidium iodide DNA content labeling and flow
cytometric cell cycle analysis was performed on the spleens of both Sfpil+/+ and
SfpilBN/BNmice. It was determined that SfpilBN/BNmice had a reduction in the percentage
of G1 phase cells, reduced from 82.2% to 67.8%, and an increase in the percentage of Sphase cells from 9.04% to 23% when compared to Sfpil+/+ littermates (Fig. 1C). This
confirmed that there was altered cell cycle in the spleens of SJpilBN/BN mice. This
suggests that the increased myeloproliferation in the SfpilBN/BN mice is due to an
unregulated Gl-S phase transition. Together, this data indicates that a reduction in PU.l
levels results in increased myeloid proliferation in the spleens of SfpilBN/BNmice.

46

Figure 3.3 SfpilBN/BNmice display increased proliferation in their spleens.
(A) RT-qPCR shows increased transcript levels of Ki-67 in SfpilBN/BN mice. RTqPCR was performed on sorted SfpilBN/BN and SJpil+/+ mice spleens (Gating strategy
shown in figure 3.11). SfpilBN/BN mice displayed increased levels of ki-67 expression
compared to Sfpil+/+ littermate controls. Each result was performed in triplicate and
significance was determined based using the students T-test. (B) Immunofluorescent
microscopy showing Ki-67 expression in splenic section. Ki-67 RT-qPCR results were
verified by immunofluorescent microscopy where frozen sections of spleen were stained
with anti-Ki-67 antibodies. Green represents Ki67 staining, blue represents DAPI
staining.
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Figure 3.4 SfpilBN/BN mice display altered cell cycle compared to Sfpil+/+ mice.
Propidium iodide DNA content labeling of SfpilBN/BNmouse spleens showed there was a
decrease in the percentage of G1-phase cells and an increase in the percentage of S-phase
cells. Graph representative of 3 separate experiments.
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3.2 Reduced PU.l levels results in increased serial colony formation ability in
differentiating cytokine conditions
Hematopoietic progenitors stimulated with GM-CSF promote differentiation, such
towards a myeloid cell type (120). Therefore, SfpilBN/BN cells were tested to determine
whether they were able to differentiate normally towards the myeloid lineage in
differentiating cytokine conditions. In addition, serial colony forming assays were
performed to determine whether these cells have lost the ability to self-renewal in-vitro.
If colony-forming capacity is arrested, then differentiated cells have lost the ability to
self-renew. To test this, timed matings were performed to obtain embryonic day 14.5
(E14.5) fetal livers. This time point was chosen since it is the time point where maximal
hematopoiesis is occurring in the livers of mice (12). After the fetal livers were
phenotyped and homogenized to single cell suspensions, they were placed in
methylcellulose media containing either GM-CSF or IL-3/ IL-6/ SCF (Figure 2.1). After
1 week total colony numbers were counted, cells were harvested, resuspended and
replated in fresh methylcellulose media containing either cytokine cocktail.
When Sfpil+/+ or Sfpil+/BN fetal liver cells were plated in GM-CSF, colony
formation occurred for approximately 2 to 3 replatings after which no colonies formed.
When SfpilBN/BN fetal liver cells were plated in GM-CSF, colony formation was
significantly higher and occurred for up to 10 replatings compared to Sfpil+/+or Sfpil+/BN
fetal liver cell controls (Figure 3.5). The experiment was terminated at the end of 10
weeks. At the end of the 10-week period, cells could be maintained in liquid culture as a
cell line. Similar results were seen when
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Figure 3.5 SfpilBN/BN fetal liver cells expressing reduced levels of PU.l can be
cultured indefinitely in GMCSF or IL3/IL6/SCF.
Colony formation assays were performed on fetal liver cells expressing wild-type allele
of PU.l (Sfpil+/+), heterozygous for BN allele (Sfpil+/BN) and homozygous for BN allele
(SfpilBN/BN) in various differentiating cytokine combinations. (A) Serial colony forming
assay in GM-CSF. Fetal liver cells were grown in the differentiating cytokine GM-CSF
after stimulation with IL3/IL6/SCF. Bar graph shows number of colonies per 50,000 cells
plated. Significance was determined used a repeated measures ANOVA followed by a
Tukey’s post test. Bar graph represents average cell count +/- standard deviation of 3
experiments. (B) Serial colony forming assay in IL-3/ IL-6/ SCF. Fetal liver cells were
grown in a differentiating cytokine combination of IL3/IL6/SCF. Bar graph shows the
number of colonies per 50000 cells plated. Significance was determined used a paired Ttest. Bar graph represents average cell count +/- standard deviation of 3 experiments. (C)
Cellular viability after transfer media supplemented with different cytokines. Cell
lines of SfpilBN/BNcultured in IL3 were washed 3 times with PBS, then cultured in media
for 72 hours containing GM-CSF, IL3 or IMDM. Bar graph shows total number of viable
cells measured by trypan blue exclusion. Graph represents average cell count +/- standard
deviation of 3 experiments.
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SfpilBN/BN cells were plated in a cytokine combination of IL-3/IL-6/SCF. These cells
were able to proliferate indefinitely, whereas the Sfpil+/BNcontrols stopped replating after
approximately 4-5 weeks (Figure 3.5B). These cells also had the ability to be maintained
as a cell line grown in liquid media containing IL-3. Furthermore, SfpilBN/BNcells, which
were grown in liquid media, could be washed and transferred into liquid culture
containing either IL-3 or GM-CSF demonstrating that they expressed the receptor for
either cytokine (Figure 3.5C). This data confirmed that hematopoietic cells with reduced
expression of PU.l were able to serially replate indefinitely in the presence of
differentiating cytokines. This shows that SfpilBN/BN myeloid progenitors are unable to
terminally differentiate to myeloid cells.

3.3 Knockdown of PU.l by miRNA results in increased colony formation in
differentiating cytokine conditions
To determine whether knocking down PU.l in Sfpil+/+ or Sfpil+/BN fetal liver
would result in increased proliferation, several miRNAs were designed to target the Sfpil
transcript. In order to assess the ability of each retroviral vector to “knock down” PU. 1
protein expression, retroviral infection of the WEHI3B myeloid cell line was performed.
Lysates were prepared from uninfected WEHI3B cells and from cells infected with each
retroviral vector, LMP-PU1.1 and LMP-PU1.3. Western blot against PU.l demonstrated
that LMP-PU.1-1 was more effective at knocking down compared to LMP-PU.1-3 (Fig.
3.6A). Densitometry suggested that LMP-PU.1-1 was able to reduce PU.l expression by
approximately 90% (Figure 3.6A).
Before performing retroviral infection on fetal liver cells, hematopoetic
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Figure 3.6 Fetal liver cells expressing normal levels of PU.l retrovirallv infected
with the PU.l silencing shRNA LMP-PU.1-1 display increased self renewal
compared to uninfected controls.
(A) PU.l knockdown Western Blot and densitometric analysis Densitometric analysis
of a Western blot comparing uninfected, LMP-PU.1-1 and LMP-PU.1-3 WEHI-3B cells.
LMP-PU.1-1 showed an approximate 90% knockdown of PU.l levels whereas LMPPU.1-3 showed an approximate 50% knockdown of PU.l levels. (B) Serial colony
forming assay following PU.l knockdown Colony formation assays were performed on
fetal liver cells expressing wild-type allele of PU.l (Sfpil+/+), heterozygous for BN allele
(Sfpil+/BN) after infection with PU.l silencing shRNA LMP-PU.1-1. Bar graph displays
total amount of colonies per 50,000 cells plated. Significance was determined used a
repeated measures ANOVA followed by a Tukey’s posttest. Graph represents average
cell count +/- standard deviation of 3 experiments.
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progenitors were enriched by performing lineage depletions on the Sfpil+/+ or Sfpil+/BN
fetal liver. E14.5 Sfpil+/+or Sfpil+/BNfetal liver cells were infected with LMP-PU.1-1 and
plated in methocellulose media containing GM-CSF. When comparing LMP1-PU.1-1
infected to uninfected Sfpil +/+cells, there was a consistent increase in the total number of
colonies and an increase in the number of weeks the colonies were able to serially replate
in GM-CSF containing methylcellulose media (Figure 3.6B). However, this increase in
colony formation was not statistically significant. When comparing LMP1-PU.1-1
infected to uninfected Sfpil+/BN fetal liver cells, there was a statistically significant
increase in the number of colonies formed and the number serial replatings in LMP1PU.1-1 infected Sfpil+/BN fetal liver cells. This was compared to uninfected Sfpil+/BN
cells, which failed to replate after 3 weeks (Figure 3.6B). In summary, this data
independently confirms that a reduction of PU.l allows for increased proliferation in the
presence of differentiating cytokine conditions.

3.4 Restoring PU.l expression in SfpilBN/BN cells results in differentiation and
reduced proliferation
Since reducing PU.l levels resulted in increased proliferation, it was hypothesized
that restoring PU.l would rescue differentiation and arrest proliferation. A retrovirus,
MigPU.l, was constructed that expresses a 3X-FLAG tagged PU.l as well as GFP.
FLAG is a polypeptide tag, which allows for efficient antibody binding. High MigRl and
MigPU.l retroviral titers were obtained by performing polyethyleneimine transfections
(Figure 3.7A). Expression of 3X-FLAG tagged PU.l was shown in NIH-3T3 cells by
Western Blot (Figure 3.7B).
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Figure 3.7 Production of MigRl and MigPU.l retroviruses.
(A) MigRl and MigPU.l transfected cells Images taken with an inverted fluorescent
microscope (Zeiss Axio-Observer) showing GFP expression in MigRl and MigPU.l
transfected PlatE cells at a lOx magnification. Scale bar represents 49.5 ym. (B) Western
blot for PU.l and FLAG from MigRl and MigPU.l infected NIH-3T3 cell lysates.
Upper panel shows Western blot using anti-PU.l antibodies of MigRl and MigPU.l
infected NIH-3T3 cells. Middle panel shows Western blot using anti-FLAG antibodies of
MigRl and MigPU.l infected NIH-3T3 cells. Lower panel shows Western blot using
anti-fi-actin antibodies of MigRl and MigPU.l infected NIH-3T3 cells.
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SfpilBN/BN cells were infected and tracked by GFP expression levels in liquid culture.
Upon infection with MigRl, the percentage of GFP+cells remained relatively
constant over the period of the experiment. This suggested that proliferation was
occurring at the same rate in infected cells as uninfected cells. Upon infection with
MigPU.l, the percentage of GFP+ cells decreased over time (Figure 3.8A). This
suggested that MigPU.l infected cells had reduced proliferation compared to uninfected
cells.
Next, to determine if self-renewal of SfpilBN/BN cells was lost upon MigPU.l
infection, serial replating assays were performed on sorted MigRl- GFP+ and MigPU. 1GFP+ cells. The results showed that MigPU.l- GFP+ cells formed significantly fewer
colonies over a period of five replating events compared to MigRl - GFP+cells. While the
MigPU.l- GFP+ cells never completely stopped forming colonies at the end of the five
replatings, it was observed that the remaining MigPU.l infected cells were no longer
expressed GFP. This may have been due to inefficient sorting or loss of MigPU.l
expression over time. These results suggest that restoring PU.l expression in SfpilBN/BN
cells results in the loss of self-renewal.
MigPU. 1 infected cells became much larger and complex intracellularly compared
to MigRl and uninfected controls (Figure 3.9). This suggested that these cells were
terminally differentiating towards the myeloid lineage. To test this idea, flow cytometry
was performed on MigRl and MigPU.l infected cells. Analysis of forward scatter
patterns, which demonstrate the relative size of the cells, revealed that MigPU.l infected
SfpilBN/BN cells were larger than MigRl infected SfpilBN/BN cells. Analysis of side scatter
patterns, which demonstrate the intracellular complexity of cells, revealed that MigPU. 1
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Figure 3.8 Self-renewal is reduced in SfpilBN/BN cells retrovirallv infected with PU.l.
(A) GFP expression in MigRl and MigPU.l infected SfpilBN/BN cells SfpilBN/BN cells
cultured in GM-CSF were retrovirally infected with PU.l (MigPU.l) or an empty
retroviral backbone as a control (MigRl). After infection, cells were cultured in media
containing GM-CSF, and GFP levels of the cells were measured at multiple time points
post-infection by flow cytometry. Graph shows relative GFP expression levels
standardized to maximal GFP expression at 48-post infection. Significance was
determined used a paired T-test. Graphs represents average cell count +/- standard
deviation of 3 experiments. (B) Serial colony forming assay of sorted MigRl-GFP+
and MigPU.l-GFP+ SfpilBN/BN cells. SfpilBN/BN cells cultured in GM-CSF were
retrovirally infected with endogenous PU. 1 or an empty retroviral backbone as a control
(MigRl) and flow cytometrically sorted to obtain a pure population of GFP+ cells, after
which cells were placed in colony forming assays with GM-CSF. Significance was
determined used a paired T-test. Graphs represents average cell count +/- standard
deviation of 3 experiments.
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Figure 3.9 MigPU.l infected SfpilBN/BNcells appear to change in morpholgy.
Upon infection with MigPU.l, cells appear to be much larger and more complex
intracellularly compared to MigRl infected cells when looking under an inverted
fluorescent microscope (Zeiss Axio-observer) at a magnification of 32x. Scale bar
represents 15.5 ym.
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Figure 3.10 SfpilBN/BN cells infected with MigPU.l increase in size, intracellular
complexity and upregulate C D llb expression
The upper panel displays a histogram of MigRl infected (open histogram) and MigPU.l
infected (filled histogram) SfpilBN/BNcells forward scatter pattern displayed as % of max
(the % of Max is the normalize amount of cells, the % of Max is the number of cells in
each bin divided by the number of cells in the bin that contains the largest number of
cells). The middle panel displays a histogram of MigRl infected (open histogram) and
MigPU.l infected (filled histogram) SfpilBN/BNcells side scatter pattern displayed as % of
max. The lower panel displays a histogram of MigRl infected (open histogram) and
MigPU.l infected (filled histogram) SfpilBN/BNcells C D llb staining pattern displayed as
% of maximum. Significance was determined used a paired T-test. Representative graph
of 3 experiments.
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infected SfpilBN/BN cells were more complex intracellularly compared to MigRl infected
SfpilBN/BN cells. Finally, analysis of CD lib , a myeloid lineage marker, showed that the
mean fluorescence intensity (MFI) was increased in MigPU.l infected SfpilBN/BN cells
compared to MigRl infected SfpilBN/BN cells, which suggest that these cells were
terminally differentiating to the myeloid lineage. In summary, these results suggest that
when PU. 1 is restored in SfpilBN/BN cells, these cells lose their ability to proliferate and
begin to terminally differentiate.

3.5 PU.l controls the cell cycle by reducing E2F1 expression levels
The experiments described above show that reduced expression of PU.l results in
increased proliferation. However, the mechanism by which PU.l might control
proliferation and the cell cycle is unknown. To determine the mechanism, transcript
levels of various cell cycle regulators were compared in Sfpil+/+ and SfpilBN/BN cells.
Spleens from Sfpil+/+ and SfpilBN/BNmice were collected and myeloid lineage cells were
sorted based on the gating strategy described in Figure 3.11 A. CD1 lb+, c-Kit' cells were
selected from Sfpil+/+ mice to represent the phenotypically normal macrophage
population. The CD1 lblow, c-Kit+population was selected in the SfpilBN/BNmice since this
is the population which represents immature myeloid progenitors and would most likely
show the largest difference in transcript levels in PU. 1 target genes. Cell cycle regulators
were analyzed by RT-qPCR including: p i6, p21, p27, Rb, e2fl, e2f2, and e2f7. CDllb
and c-Kit acted as internal controls for the RT-qPCR reactions since the cells were sorted
based on CDllb and c-Kit levels. The only regulator for which transcript levels were
significantly changed was E2F1, which promotes G1 to S phase progression.

Figure 3.11 Determining cell cycle regulators under the control of PU.l using
SfpilBN/BNand Sfnil+/+mice.
(A) Gating strategy for cell sorting. The gating strategy used to obtain myeloid cells
used to compare transcript levels between SfpilBN/BN and Sfpil+/+ mice. Cells used for
RT-qPCR include C D llb+c-Kit' from S fp il'/+ mice as well CD1 lb'°c-Kit+ from
SfpilBN/BN mice (B) Changes in transcript levels of various cell cycle regulators
between SfpilBN/BN and Sfpil+/+ mice. RT-qPCR was performed on multiple cell cycle
regulators. The y-axis shows the fold change between control Sfpil+/+mice and SfpilBN/BN
mice using the comparative threshold cycle method. Each result was performed in
triplicate and significance was determined using the students T-test.
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Figure 3.12 Identification of cell cycle regulators by comparing transcript levels in
MigRl and MigPU.l infected SfpilBN/BNcells
(A) Gating strategy of cell sort Sfpilm/BN cells cultured in GM-CSF were retrovirally
infected with endogenous PU.l (MigPU.l) or an empty retroviral backbone as a control
(MigRl) and then sorted to obtain a pure population of GFP+ cells, after which RNA was
collected. (B) Fold-changes in transcript levels of cell cycle regulators between
MigRl and MigPU.l infected SfpilBN/BN cells RT-qPCR was performed to compare
transcript levels between MigRl infected and MigPU.l infected SfpilBN/BNcells using the
comparative threshold cycle method. Each result was performed in triplicate and
significance was determined based using the students T-test.
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To confirm that PU.l was affecting E2F1 transcription, SfpilBN/BN cells were
infected with MigRl and MigPU.l retroviruses, after which GFP+ cells were sorted to
collect total RNA (Figure 3.12A) C D llb and c-Kit acted as internal controls since
CD lib is a target of PU.l and should increase upon infection, whereas c-Kit should
decrease upon infection (118). The following regulators of the cell cycle were analyzed
by RT-PCR: cMyc, c/EBPa, Tyms, PolAl, CDK6, skp2 and E2F1. E2F1 transcript levels
were down regulated upon MigPU.l infection, which is consistent with RT-PCR data
collected from in vivo samples. While the decrease was not statistically significant it
showed a positive correlation suggesting that PU.l is regulating the transcript levels of
E2F1. This data suggests that PU.l is at least partly controlling the cell cycle by
regulating the transcription levels of E2F1.

3.6 SfpilBN/BNcells develop an osteopetrotic phenotype
In addition to their myeloproliferative phenotype, SfpilBN/BN mice also displayed a
runted and osteopetrotic phenotype (Figure 3.1). When comparing the shape of the skulls
between SfpilBN/BN and Sfpil+/+ mice, it appeared that SfpilBN/BN mice had a malformed
skull. Dissection of the skull was performed to identify any abnormalities. Skulls were
stained with alzarin red, which stains mineral deposits bone, as well as alcain blue, which
stains collagen found in cartilage. Figures 3.13A and 3.13B show a lateral view of the
mouse skulls. 20-day-old SfpilBN/BN mice lacked teeth, whereas Sfpil+/+ mice displayed
normal tooth formation. An overhead view shows a reduction in the size of the skull
plate, particularly the frontal plate in the SfpilBN/m mice when compared to Sfpil+/+ mice
(Figure 3.13C and 3.13D). Furthermore, the fontenelle failed to fuse in SfpilBN/BNmice as

Figure 3.13 Alzarin red and alcain blue staining of SfpilBN/BN and Sfpil+/+ mouse
skulls.
Red staining indicated mineral deposits in bone, blue staining indicates collagen staining
in cartilage. (A, B) Lateral view of the mouse skulls; SfpilBN/BN mice lack tooth
eruption. (C, D) Overhead view of mouse skulls. SfpilBN/BNmice have a reduction in the
size of the skull plate, specifically the frontal plate. (E, F) Overhead view of mouse
skulls. SfpilBN/BN mice lack of fontenelle fusion and a have general reduction in the
thickness of bone in the skull. (A)(C)(E) S fp il'" mice (B)(D)(F) SfpilBN/BNmice. Scale
bar is representative of 1 mm. Image representative of 1 experiment.
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well an apparent reduction in bone thickness and density (Figure 3.13E, 3.13F).
Next, immunohistochemical (IHC) staining of the hypertrophic chondrocyte p57
was performed. In Sfpil+/+ mice, a distinct hypertrophic zone was observed within the
growth plate based on high levels of p57 expression (Figure 3.14). However in SJpilBN/BN
mice, p57 expression was downregulated. The remaining p57 expression showed no
distinct hypertropic zone and the proliferating zone of these cells was elongated (Figure
3.14). This data suggests that reduced PU.l may affect p57 expression, which resulted in
chondrocytes not being able to exit the cell cycle and terminally differentiate into
hypertrophic chondrocytes.
Since osteoclasts are of the myeloid lineage, tartrate resistant acid phosphatase
(TRAP) staining was performed to determine whether osteoclast function was
contributing to the runted phenotype. TRAP stains were performed on Sfpil+/+ mouse
femur and tibia, which showed staining of normal TRAP"1"osteoclasts within the growth
plate, indicating that osteoclasts are present (Figure 3.15). However, in SfpilBN/BN mouse
femur and tibia, there was a lack of TRAP+ osteoclasts within the samples. This result
indicated a defect in osteoclast development in SfpilBN/BN mice. In summary, reduced
expression of PU. 1 resulted in an osteopetrotic phenotype, which was characterized by
various skeletal defects including reduced numbers of p57+ chondrocytes and a lack of
TRAP+ osteoclasts.

Figure 3.14 p57 immunohistochemical (IHC) staining of the growth plate.
IHC was performed on p57 on the growth plate of control Sfpil+/+ and SfpilBN/BN mice.
Images shown were taken using a Retiga EC camera connected to a Leica DMRA2
fluorescence microscope at lOx and 40x magnification. Primary analyses were performed
using OpenLab 4.0.4. software. lOx scalebar is representative of 97 ym. 40x scalebar is
representative of 15 ym. Image representative of 2 experiments.
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Figure 3.15 Tartrate Resistant Acid Phosphatase (TRAP) staining of the growth
plate in tibia and femur.
TRAP staining was performed on the femur and tibia of control Sfpil+/+ and SfpilBN/BN
mice. TRAP+ cells are seen in purple. Images shown were taken using a Retiga EC
camera connected to a Leica DMRA2 fluorescence microscope at 5x magnification.
Primary analyses were performed using OpenLab 4.0.4. software. Scale bar is
representative of 192 ym. Image representative of 2 experiments.
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CHAPTER 4: DISCUSSION
4.1 Overview
In this project we hypothesized that a reduction of PU. 1 levels would result in the
development of AML through dysregulation of the cell cycle, resulting in increased
proliferation of myeloid progenitors. Furthermore, reduced PU.l would also result in a
block in terminal myeloid differentiation. The primary objective was to characterize the
SjpH BN/BN mouse phenotype, which was previously generated by our lab but incompletely

characterized. This work identified an exapansion of immature myeloid lineage cells
occurring in the spleens of the mice and also characterized the osteopetrotic phenotype
displayed by these mice. The second objective was to determine whether a reduction in
PU.l leads to increased myeloid cell self-renewal, addressed by performing serial colony
forming assays. The final objective was to determine the mechanism by which PU.l
controls proliferation, which was completed by identifying changes in transcript levels
between cells expressing low and high levels of PU.l. Our findings support our
hypothesis that a reduction of PU.l levels results in the development of AML through
dysregulation of the cell cycle, resulting in increased proliferation of myeloid
progenitors. By accomplishing these objectives we have a greater understanding of the
role of PU.l in the development of AML and the mechanism by which PU.l is causing
AML.
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4.2 Cells with reduced PU.l expression have increased self-renewal and acquire
hallmarks of cancer.
This aim of this project was to characterize the SfpilBN/BNmouse phenotype and to
show that a reduction in PU.l expression resulted in abnormalities in myeloid
differentiation. Analysis of the phenotype was performed by examining the spleen of the
SfpilBN/BN mice and determining whether there was increased proliferation. It was
determined that SfpilBN/BNmice had a significant expansion of CD1 lb+, c-Kit+ immature
myeloid lineage cells within their spleens and Ki-67 protein levels were increased
indicating increased proliferation. Furthermore, the spleens of SfpilBN/BNmice displayed
altered cell cycle signified by the decrease in the percentage of G1 phase cells and an
increase in S phase cells. This suggests increased proliferation is occurring in the spleens
of SfpilBN/BNmice due to unregulated transition between the G1 and S-phase of the cell
cycle.
As mentioned previously, the cell cycle is a tightly regulated process that has
checkpoints to ensure proper progress. Breakdowns in cell cycle regulation may result in
uncontrolled proliferation and cancer. This demonstrates that PU.l levels affect one of
the six hallmarks of cancer that were originally proposed in 2000 (121). The original six
hallmarks include: 1) insensitivity to anti-growth signals 2) self-sufficiency in growth
signals 3) evading apoptosis 4) tissue invasion and metastasis 5) sustained angiogenesis
6) limitless replicative potential (121). These hallmarks have been updated recently with
the following hallmarks being added: 7) deregulating cellular energetics 8) avoiding
immune destruction 9) tumor-promoting inflammation 10) genome instability & mutation
(122).

Increased proliferation within the spleen demonstrates the first hallmark of
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insensitivity to anti-growth signals within the spleen. In a normal situation, myeloid
progenitors receive signals to enter a differentiated state and the cell cycle is arrested,
however cancerous cells evade these signals and continue to proliferate. The G1 to S
phase transition is particularly important since many oncogenes and tumor suppressors
are associated with this checkpoint such as p53, retinoblastoma protein (Rb) and the E2F
family of genes (123). These results imply that PU.l may be directly regulating the
expression of G1 to S phase regulators due to the altered cell cycle status of these cells.
Another hallmark of cancer and stem cells is limitless replicative potential
otherwise known as self-renewal. Self-renewal is defined as the ability to undergo many
cellular divisions while remaining undifferentiated. This ability is characteristic of
hematopoietic stem cells and is lost during the process of differentiation. However,
leukemic cells either retain this ability since they exhibit a differentiation block where
they have not yet lost self-renewal ability or gain this ability by acquiring a mutation that
allows self-renewal. Self-renewal ability was tested by performing serial colony-forming
assays in methylcellulose media. This was confirmed by two separate tests. The first test
was completed by collecting embryonic day 14.5 (E14.5) fetal liver cells from Sfpil+/+,
Sfpil+/BN' and SfpilBN/BNmice and placing them in methylcellulose media in the presence
of the differentiating cytokines GM-CSF or in IL-3/IL-6/SCF. The second test was
performed by retroviral infection containing a miRNA against PU. 1, and knocking down
PU.l expression in Sfpil+/+ and Sfpil+/BN hematopoietic progenitor cells. Both of these
tests demonstrated that reduced levels of PU. 1 resulted in colony formation that occurred
for significantly more replatings, which suggested that these cells have increased self
renewal.
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Serial colony forming assays provide useful information about the proliferative
ability of cells in vitro, however the limitations of this assay must be acknowledged.
Ideally, in vitro assays should be: quantitative, specific (measuring only the cells of
interest), sensitive (many of the target cells are present at low frequency), and rapid
(when compared to in vivo assays). These assays were performed in methylcellulose
media that is well-defined media for demonstrating the proliferative ability of cells in
differentiating cytokine conditions, with colony formation as a readout (124).
Unfortunately these assays are not able to differentiate between the types of cells that are
forming the colonies, either stem cells or progenitors that retained self-renewal capacity.
These assays are not able to maintain stem cells efficiently since they are not the proper
niche and do not provide the signals required to maintain self-renewal which are
normally provided by the microenvironment. The cobblestone area-forming assay
(CFAC) is one method to provide necessary signals since this assay utilizes a preestablished stromal layer, however it is labour-intensive (124). The gold standard for
determining self-renewal capacity is performing in vivo serial transplantation assays (13,
125, 126). In these assays cells are first transplanted into a recipient mouse and evaluated
for leukemia at various time points. If leukemia is detected, these cells are then engrafted
to a second recipient mouse and tested for leukemia as before. While in vivo
transplantation assays require much time as well as expenses, they remain the conclusive
assay to demonstrate self-renewal.
Since reduced levels of PU.l resulted in increased proliferation and self-renewal,
the next objective was to determine whether restoring PU.l expression forces
differentiation of SfpilBN/BN cells and causes the cells to reverse their self-renewal
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capacity. This was completed by infecting SfpilBN/BNcell lines with MigPU.l, a retrovirus
that constitutively expressed PU.l as well as a GFP marker. Upon retroviral infection
with MigPU.l, cells displayed reduced ability to proliferate and a loss in self-renewal
capacity as demonstrated in serial colony forming assays as well as liquid assays.
Furthermore, upon infection with MigPU.l, SfpilBN/BN cells showed signs of
differentiation by changing their morphology and expressing terminally differentiation
markers (CDlib). Together, this data demonstrates that PU.l expression levels regulate
self-renewal in cells of the myeloid lineage in vitro. Low levels of PU.l expression result
in increased self-renewal as well as proliferation whereas high levels of expression of
PU.l result in decreased self-renewal and promoted the ability to differentiate in the
myeloid lineage.
All of these results were performed in SfpilBN/BN mice, however an alternative
mouse model exists for graded reduction of PU.l. This mouse model was created by Dr.
Tenen’s group where an upstream regulatory region (URE) which decreased PU.l
expression by 80%. There are both similarities and differences when comparing the
SfpilBN/BN mice and the URE knockout mice. Both models display a reduction in PU.l
expression levels within the myeloid lineage, however unlike SfpilBN/BN mice which
display a global knockdown of PU.l levels, the URE knockout mice display a PU.l
knockdown in particular lineages, whereas other lymphoid lineages display an increase in
PU.l expression. Another similarity is both models with a reduction in PU.l die due to
their reduction in PU.l, however, the SfpilBN/BN mice die at around 21 days of age
whereas the SfpilBN/BN mice die anywhere from 3-9 months. Both of these mouse models
experience an increase in immature myeloid cells, which are c-Kit+, C D llb+ and Gr-1+.
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Once significant difference between the two mice is that URE knockout mouse does not
exhibit the same osteopetrotic phenotype as the SfpilBN/BN mice. This is an unusual
observation since osteoclasts, which remodel bone, are part of the myeloid lineage and
many factors required to differentiate into myeloid cells are under the control of PU. 1.
While the reason for the lack the osteopetrotic phenotype is unknown, it demonstrates the
need for multiple models since each model may reveal different information.

4.3 The mechanism by which PU.l alters the cell cycle
While PU.l has been implicated in the development of AML, the role by which
PU.l is affecting the cell cycle is poorly understood. PU.l has been shown to act as both
a transcriptional activator and a repressor of various genes (127, 128). PU.l was shown to
affect proliferation in part through deregulated cell cycle progression at the G1 to S phase
transition. Therefore, we hypothesized that PU.l expression may be controlling G1 to S
phase transition either by activating a gene involved in cell cycle repression, or repressing
a gene involved in cell cycle progression.
To determine potential target genes of PU.l, quantitative real-time PCR was used to
determine transcript level changes based on PU.l expression levels. Two separate
strategies were utilized to collect RNA samples. The first strategy utilized SfpilBN/BNcells
that were infected with MigRl and MigPU.l and then sorted the MigRl-GFP+ infected
SfpiJBN/BN cells and MigPU.l-GFP+ infected SfpilBN/BN cells to obtain pure populations,
which were used to measure differences in transcript levels. The second strategy utilized
Sfpil+/+ and SjpilBN/BN mice and compared the transcript levels of sorted populations in
the spleens. Sfpil+/+ C D llb+, c-Kit'° and SfpilBN/BN C D llblow, c-Kit+ cells were sorted
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and used to compare gene transcript levels. This gating strategy was used because it was
hypothesized that the greatest differences in transcript levels would be seen in these
populations. Sfpil+/+ C D llb+, c-Kit'° cells were representative of differentiated
macrophages and were expected to have displayed normal cell cycle regulatory transcript
levels, whereas SfpilBN/BN c-Kit hl C D llblow cells were immature myeloid lineage cells
still regulated by PU. 1. However they should have had altered levels of gene expression
due to the low levels of PU.l expression.
Since PU.l was shown to influence the G1 to S phase cell cycle checkpoint, many
cell cycle regulators were analyzed to determine whether they were controlling the cell
cycle. The first hypothesis tested was whether Tyms, Pola and Skp2 transcript levels were
altered by PU.l. The rationale behind this hypothesis was that these genes are under the
transcriptional control of Gabpa, which is a member of the ETS transcription factor
family (129). Since all ETS family transcription factors have ETS DNA binding domains
which bind to the same GGAA core motif (130), it is reasonable to believe that PU.l may
target the same genes but have a different effect. Tyms, Pola and Skp2 are all required for
cell cycle progression, particularly into S-phase for several reasons. The role of Tyms is
to generate the deoxynucleotide dTTP (131), Pola is the DNA polymerase a p i80
catalytic subunit that initiates DNA replication in S phase (132), Skp2 is an E3 ligase that
regulates the cell cycle-dependent ubiquitination and degradation of cell cycle inhibitors
p21 and p27 (133). Therefore, our hypothesis was that one or more of Tyms, Pola or Skp2
would be transcriptionally repressed by high levels of PU.l expression. RT-qPCR
analysis found that these transcript levels remained relatively unchanged upon MigPU. 1
infection, suggesting that PU. 1 does not control the cell cycle through these genes.
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cMyc, cEBPa and CDK6 were also tested by RT-qPCR to determine whether their
transcript levels changed upon MigPU. 1 infection. cMyc was chosen as a target since it is
a gene commonly affected in many cancers, and was shown to be upregulated in other
models where PU.l is downregulated (76). cEBPa was chosen since it is also a
transcription factor mutated in many forms of AML and finally CDK6 since it is
important for G1 to S phase progression in the cell cycle (107, 134). RT-qPCR once
again revealed no significant changes in transcript levels upon MigPU. 1 infection.
Due to the technical difficulty of infecting SfpilBN/BN cells with retrovirus, the
following sets of genes were tested by comparing transcript levels in Sfpil+/+ and
SfpilBN/BN mouse spleens. The first set of proteins that were tested were: p i 5, p i 6, p21
and p27. PI 5 and p i 6 were chosen since they are members of the INK4 family of cell
cycle progression inhibitors and levels of these proteins have been shown to be altered in
cases of AML, as well as interact with PU.l (135, 136). P21 and p27 were chosen since
they are members of the Cip/Kip family of cell cycle progression inhibitors (137). No
transcripts of pi 5 were detected by RT-qPCR (Data not shown). Furthermore, RT-qPCR
was performed on p i 6, p21 and p27 and it was shown that transcript levels for these
genes were not significantly changed for any of these cell cycle regulators.
Next, retinoblastoma protein (Rb), e2fl, e2f2 and e2f7 transcript levels were
compared by RT-PCR. Rb was chosen since it is a regulator of the E2F family of
transcription factors, which controls the transcription of S-phase genes. Furthermore, it
has been implicated in multiple cancers. The E2F family of genes is essential in the
regulation of cellular proliferation and function in both an activating and repressive
manner. E2fl and e2f2 are transcriptional activators that allow for G1 to S phase
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progression. Overexpression of these transcription factors is sufficient to cause quiescent
cells to reenter the cell cycle (111). Furthermore, in certain situations, overexpression of
these transcription factors may override growth arrest signals (138-140). E2fl was also
tested since it is a transcriptional repressor and blocks cellular proliferation (141, 142).
When RT-qPCR was performed on Rb, e2F2 and e2fl, there were no significant
changes found in the transcript levels. Conversely, when E2flwas tested it was found that
transcript levels of e2fl were significantly increased in SfpilBN/BN mice where PU.l is
reduced. This supports the hypothesis that PU.l would function by inhibiting a cell cycle
regulator that promotes cell cycle progression. To confirm the results seen in Sfpil+/+ and
SfpilBN/BN sorted cells, e2fl transcript levels were tested in SfpilBN/BN cells infected with
MigRl and MigPU.l. Upon MigPU.l infection, e2fl transcript was decreased, although
it did not meet statistical significance. Overall these results suggest that PU.l expression
levels may be regulating e2fl levels, where low levels of PU. 1 resulted in increased e2fl
transcript levels which in turn result in increased proliferation.
While we have shown that PU. 1 correlates with e2fl expression, the mechanism by
which PU.l is regulating the expression remains unclear. We hypothesize that PU.l may
be regulating e2fl by activating another regulator which in turn blocks e2fl transcription,
or by directly regulating the promoter region and repressing its expression, or a
combination of the two. We have generated a working hypothesis that PU.l regulates
e2fl transcript levels by regulation of a microRNA, miR-223. Previous data supporting
the notion that PU.l activates the expression of miR-223 in the myeloid lineage (143).
MicroRNAs are tiny noncoding RNAs, which regulates the expression of target genes by
binding to complementary sequences in the target gene resulting in transcript degradation
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or translational repression (144). MiR-223 knockout mice display defects in
granulopoiesis (145). Furthermore, miR-223 is inactivated by the AML1/ ETO fusion
oncoprotein, which is present in many forms of AML (146). It has also been shown that
miR-223 targets e2fl and forms a negative feedback loop repressing e2fl (147).
Therefore we hypothesize that PU.l is regulating the expression microRNA, miR-223,
which in turn regulates e2fl. Under normal conditions when PU.l is expressed at high
levels in differentiated myeloid progenitors, this would result in high levels of expression
of miR-223 and in suppression of e2fl and cell cycle progression beyond the Gl-S phase
boundary. However, when PU.l expression is repressed, miR-223 is not expressed
resulting in increased E2F1 expression and continual cell cycle progression (Figure 4.1).
Another mechanism by which PU.l may be regulating e2fl is by directly regulating the
promoter of e2fl. Chromatin immunoprécipitation studies of PU. 1 have shown the ability
of PU.l to bind directly to the E2F1 promoter (148).
In summary, we have shown that PU. 1 expression correlates with transcript levels
of e2fl. However, it remains to be determined whether e2fl is directly regulated by PU.l
or if this is performed through e2fl is regulated by PU.l indirectly through miR-223.

4.4 The osteopetrotic phenotype of SfpilBN/BNmice
In addition to their myeloproliferative phenotype, SfpilBN/BN mice also appear
runted. This phenotype was investigated in greater detail to establish the role of PU.l in
skeletal development. First, SfpilBN/BNand Sfpil+/+mouse skulls were stained with alzarin
red to stain mineralized tissue and alcain blue which stains cartilage. It was observed that
20-day-old mice SfpilBN/BNmice had no tooth eruption, reduced skull plate, lack fontelle

Figure 4.1 Proposed Mechanism of PU.l regulation of E2F1
(A) Mechanism during normal PU.l expression levels. In situations where PU.l is
expressed at normal levels, PU.l activates miR-223 transcription. Upon transcription,
miR-223 blocks e2fl translation, which results in G1 to S phase arrest. (B) Mechanism
during reduced PU.l expression levels. In situations where PU.l is expressed at low
levels, PU.l is unable to activate miR-223 transcription. This results e2fl transcription
and translation allowing cell cycle progression. Furthermore, e2fl further represses miR223 transcription through a negative feedback loop.
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fusion, and had a general reduction in density and thickness when compared to Sfpil+/+
mouse littermates. This suggests that the mice develop some form of osteopetrosis since
they are unable to remodel their bone, demonstrated with the lack of tooth eruption.
Next, the growth plates of the long bones were analyzed for p57 expression. P57
is a cell cycle regulator that arrests cells in the G1 phase. Furthermore, it is a marker that
is expressed in hypertrophic chondrocytes. Immunohistochemistry was performed on
SfpilBN/BN mouse sections, which showed there was decreased staining for p57 and the
hypertrophic zone was less distinct compared to Sfpil+/+ littermates. This was an
unexpected finding since PU.l is expressed exclusively in the hematopoietic system
meaning the growth plate was not expected to be affected. Nevertheless, the chondrocytes
were not able to exit the cell cycle and differentiate into hypertrophic chondrocytes.
Finally, osteoclast activity was also examined by performing tartrate-resistant acid
phosphatase (TRAP) staining. TRAP is a marker of osteoclast function, and is highly
expressed on osteoclasts (98, 149). It is also expressed at low levels on activated
macrophages, dendritic cells and other cells at low levels(149). There was no TRAP+
staining on SfpilBN/BNmice within the growth plates or trabecular bone of both the femur
and the tibia. This result was to a certain extent expected since macrophage colony
stimulating factor receptor (M-CSFR) is regulated by PU. 1 and M-CSF is required for the
differentiation of macrophages (150). Similar results are seen in the osteopetrotic op/op
mice, which have a mutation in m-csf. Together, these results demonstrate that PU.l
plays a significant role in skeletal development and disease.
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4.5 Future directions
This project provided insight into the role that PU.l plays in the development and
regulation of AML. However, there are still many questions that need to be addressed.
The first question is whether PU. 1 is regulating e2fl expression directly or indirectly. In
this project, it was shown that PU.l expression regulates the amount of E2F1 transcript
levels. However, it was not determined conclusively what is the mechanism which PU.l
is performing the function. Some evidence suggests that PU.l may directly regulate E2F1
expression (148). Therefore it would be interesting to prove whether PU.l is directly
regulating e2fl in SJpil+/+ and SfpilBN/BN mice. By performing a chromatin
immunoprécipitation for PU.l we can determine whether PU.l is found on the promoter
region of E2F1. If this is the case, many avenues of research may be available such as
performing biochemical analysis to determine which regions are interacting with the
E2F1 promoter. If it is determined that PU.l is not directly interacting with the promoter,
it would be necessary to determine what pathway leads to these effects. It was mentioned
that PU.l is able to regulate E2F1 functions through miR-223 (147). This would also
need to be verified experimentally. It would also need to be determined if this was the
only form of regulation, or whether miR-223 acts to fme-tune the actual mechanism since
it has been shown that many microRNAs act by fine tuning transcript levels of genes.
Once the mechanism is elucidated, the next step will be to conclusively determine
whether the proliferation occurring in the spleens of these mice is AML. The gold
standard to determine whether this is leukemia would be to perform transplantation
experiments in vivo. While it is known that primary engraftment does occur (unpublished
data), it must still be determined whether the recipient mice develop any form of AML.

93

Limiting dilution transplantation experiments would be necessary to determine the
frequency of cells that are leukemic stem cells. Additionally, hematopathology and
histology should be completed on these mice to determine whether their white blood cell
count and differential is altered. These experiments are critical in establishing the AML
diagnosis in this model and would strengthen the conclusions from this project.
Finally, an interesting avenue of research would be to determine whether the
transcription factor SpiB is acting redundantly to PU.l. Our lab has observed that
CD19+,a%Sfpilhx/,m, SpiB', develop a pre-B cell acute lymphoblastic leukemia before 30
weeks of age (151). SpiB is an ETS family transcription factor that has high homology to
PU. 1 and has been shown to act redundantly in other cell types. Therefore, it would be
interesting to determine whether the mice which pass away earlier develop AML.
Furthermore, it would be interesting to cross the SfyilBN/BNmice to SpiB in the hopes of
breeding SfpilmBK, SpiB- mice to investigate whether these mice first survive, and also
whether they develop AML more frequently or a more aggressive form of AML than
SfpilBBBSalone. This will help us determine whether the same redundancy in the myeloid
cell lineage as is seen in the B cell lineage.
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4.6 Summary and Conclusions
The goal of this project was to determine the role of PU. 1 in the regulation of self
renewal in AML. I hypothesized that reduced levels of PU.l cause AML by promoting
self-renewal of myeloid progenitors through deregulation of the cell cycle, which results
in increased proliferation and a block in terminal differentiation; where I define self
renewal as an increase in cell division in the absence of differentiation. This work has
shown to be in support of the central hypothesis. This work demonstrated that a reduction
of PU. 1 expression resulted in unregulated proliferation of immature myeloid lineage
cells in the spleen by an increased G1 to S phase transition. Furthermore, reduced
expression of PU. 1 in SfpilBN/BN fetal liver cells resulted in increased self-renewal and
proliferation; whereas restoring PU.l expression in SfpilBN/BNcells resulted in diminished
proliferation and differentiation. We determined that PU.l controls the cell cycle through
regulation of e2fl transcription, however it remains to be determined whether this is
direct or indirect effect. Finally, this project characterized the osteopetrotic phenotype in
SfpilBN/BN mice.

These mice lack TRAP+ osteoclasts within the growth plate and

trabecular bone as well as reduced expression of p57 which marks differentiated
hypertrophic chondrocytes. Together, these results suggest that reduced PU.l expression
results in increased myeloid cell self-renewal, which then promotes an AML-like
phenotype.
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APPENDIX
Animal Use Protocol

04.24.09
‘This Is the Original Approval for this protocol*

*A Full Protocol submission will be required in 2013*
Dear Dr. DeKoter:
Your Animal Use Protocol form entitled:
Regulation of Myeloid Versus Lymphoid Cell Fates by PU.1
Funding Agency Departmental
has been approved by the University Council on Animal Care. This approval is valid from 04.24.09 to 04.30.10.
The protocol number for this project is 2009-010.
1. This number must be indicated when ordering animals for this project.
2. Animals for other projects may not be ordered under this number.
3. If no number appears please contact this office when grant approval is received.
If the application for funding is not successful and you wish to proceed with the project, request that an internal
scientific peer review be performed by the Animal Use Subcommittee office.
4. Purchases of animals other than through this system must be cleared through the ACVS office. Health certificates
will be required.
ANIMALS APPROVED FOR 4 Years
Species

Strain

Other Detail

Pain
Level

Animai # Total
for 4 Years

Mouse

Various
(as outlined in
Protocol)

As Outlined in protocol

D

3319

REQUIREMENTS/COMMENTS

Please ensure that individual(s) performing procedures on live animals, as described in this protocol, are familiar with
the contents of this document.

The holder of this Animal Use Protocol is responsible to ensure that all associated safety
components (biosafety, radiation safety, general laboratory safety) comply with institutional
safety standards and have received all necessary approvals. Please consult directly with your
institutional safety officers.
Hazards have been identified as part of this protocol
- Level 2 animals are not permitted to be taken to Robarts for irradiation
- Please contact Vet Services before using the higher dose (1100cGy) of irradiation

c .c .

M Pickering, W Lagerwerf

The U n i v e r s i t y o f W

e ste rn O n ta rio

Animal Use Subcommittee / University Council on Animal Care
Health Sciences Centre, ! London, Ontario ! CANADA - N6A 5C1
PH: 519-661-2111 ext.86770! F L 519-661-2028 ! www.uwo.ca/animal

